Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.03−0.30 (-22.56%)
Close on Nov 18, 2026Market cap $96.53MP/E –Yield –
Innate Pharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was -€52.90M. The highest annual figure on record is €33.65M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€52.90M | – |
| FY2024 | Dec 31, 2024 | -€7.29M | – |
| FY2023 | Dec 31, 2023 | -€32.91M | – |
| FY2022 | Dec 31, 2022 | -€19.69M | – |
| FY2021 | Dec 31, 2021 | -€59.39M | – |
| FY2020 | Dec 31, 2020 | -€52.67M | -256.5% |
| FY2019 | Dec 31, 2019 | €33.65M | – |
| FY2018 | Dec 31, 2018 | -€33.40M | – |
| FY2017 | Dec 31, 2017 | -€51.02M | – |
See a number that looks wrong?